Journal
TRENDS IN MOLECULAR MEDICINE
Volume 11, Issue 2, Pages 82-89Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.molmed.2004.12.006
Keywords
-
Ask authors/readers for more resources
Mutations in the mu-opioid receptor - the primary site of action of opioid analgesics - are candidates for the variability of clinical opioid effects. This has been substantiated by recent advances in genetic research. A common p-opioid receptor polymorphism was associated with higher demands for alfentanil or morphine for pain relief. It also decreased the potency of morphine for pupil constriction and experimental analgesia, but its molecular mechanisms are unclear. Another opioid receptor mutation greatly impaired receptor signalling in vitro, but is very rare. The accumulated evidence provides a solid basis for continuing research that should address the underlying molecular mechanisms and the role and benefits of OPRM1 genotyping for clinical pain therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available